Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate zanzalintinib showing potential to offset future revenue losses.

Matthew R. Zibelman, MD, discusses treatment options in muscle-invasive, perioperative, and metastatic bladder cancer.

Like a champion boxer on the ropes, Bristol-Myers Squibb (NYSE: BMY) finds itself in a challenging position. Specifically, ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...

International Assets Investment Management LLC cut its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 98.4% ...

Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...

Opdivo is currently the market leader in PD-1/PD-L1 immunotherapies, but Merck’s rival Keytruda is tipped to overtake it, thanks to its approval in first line use against non-small cell lung cancer.

"" class="type:primaryImage wp-post-image" height="1280" src=" width="720" data-uuid="f15a9b71-00a0-392c-b74f-a8e400fa8aa8"> ...

January is “National Radon Action Month” and state and local health departments are encouraging everyone to test their homes ...

The US says forces active within Sudan are guilty of many of the same war crimes that Israel is accused of. Tehran denies Sala’s December 19 detainment was linked to an Iranian businessman’s ...